Semaglutide News and Research

Latest Semaglutide News and Research

Semaglutide provides double benefit for women with heart failure

Semaglutide provides double benefit for women with heart failure

Novo Nordisk presents key findings from semaglutide trials at ADA scientific sessions 2024

Novo Nordisk presents key findings from semaglutide trials at ADA scientific sessions 2024

Semaglutide weight loss results linked to diabetes severity

Semaglutide weight loss results linked to diabetes severity

The USPSTF recommend clinicians refer children and adolescents 6 years or older with a high BMI to intensive behavioral interventions

The USPSTF recommend clinicians refer children and adolescents 6 years or older with a high BMI to intensive behavioral interventions

GLP-1 agonists linked to reduced dementia risk in type 2 diabetes patients

GLP-1 agonists linked to reduced dementia risk in type 2 diabetes patients

WHO issues medical product alert on falsified semaglutides

WHO issues medical product alert on falsified semaglutides

Oral semaglutide proves effective for type 2 diabetes and weight loss in Dutch study

Oral semaglutide proves effective for type 2 diabetes and weight loss in Dutch study

New dietary recommendations for patients on latest anti-obesity medications like Ozempic

New dietary recommendations for patients on latest anti-obesity medications like Ozempic

Safety-focused summary of GLP-1 receptor agonists in diabetes, obesity, and beyond

Safety-focused summary of GLP-1 receptor agonists in diabetes, obesity, and beyond

Wegovy and Ozempic linked to reduced incidence and recurrence of alcohol abuse or dependence, study suggests

Wegovy and Ozempic linked to reduced incidence and recurrence of alcohol abuse or dependence, study suggests

Research points to a potential approach to mitigating diabetes risk from antipsychotic medications

Research points to a potential approach to mitigating diabetes risk from antipsychotic medications

Pre-surgery GLP-1 agonists reduce post-operative risks in extreme obesity

Pre-surgery GLP-1 agonists reduce post-operative risks in extreme obesity

Metabolic surgery proven most effective for sustained weight loss over GLP-1 drugs and lifestyle interventions

Metabolic surgery proven most effective for sustained weight loss over GLP-1 drugs and lifestyle interventions

Innovative therapeutic strategies for combating type 2 diabetes

Innovative therapeutic strategies for combating type 2 diabetes

Two diabetes medications more beneficial in preventing major cardiovascular events

Two diabetes medications more beneficial in preventing major cardiovascular events

Insurance denials hinder GLP1Ra use in children and teens with type 2 diabetes

Insurance denials hinder GLP1Ra use in children and teens with type 2 diabetes

Weight loss drug may change how obese people perceive taste

Weight loss drug may change how obese people perceive taste

Tirzepatide treatment results in successful weight loss regardless of obesity-related complications

Tirzepatide treatment results in successful weight loss regardless of obesity-related complications

GLP-1 drugs may reduce pancreatitis risk in obese and diabetic patients

GLP-1 drugs may reduce pancreatitis risk in obese and diabetic patients

Oral semaglutide shows significant promise in improving diabetes control and cardiovascular health, study reveals

Oral semaglutide shows significant promise in improving diabetes control and cardiovascular health, study reveals

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.